JW Pharmaceutical says Korea FTC files Supreme Court appeal in antitrust fine case

• JW Pharmaceutical corrected its fines disclosure to add that Korea’s Fair Trade Commission filed a Supreme Court appeal on Oct. 8.
• The company also filed its own appeal on Oct. 1, following a Seoul High Court ruling that partially canceled the penalty payment order.
• The case concerns an administrative fine tied to alleged improper customer inducement through economic benefits.
• KRW 29.902 billion was paid on Jan. 18, 2026, though the final liability remains unresolved pending the Supreme Court process.
• The regulator may recalculate and reimpose the fine depending on the Supreme Court’s decision.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. JW Pharmaceutical Corporation published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261008800667), on October 08, 2026, and is solely responsible for the information contained therein.